A Phase 3, Randomized, Double‐Blind Study of Pembrolizumab versus Placebo in Combination With
Adjuvant Chemotherapy With or Without Radiotherapy for the Treatment of Newly Diagnosed High‐Risk Endometrial Cancer After Surgery With Curative Intent
Sponsor: Merck Sharp & Dohme Corp.